These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 304802)

  • 61. Corynebacterium parvum: a synonym for Propionibacterium acnes?
    Cummins CS; Johnson JL
    J Gen Microbiol; 1974 Feb; 80(2):433-42. PubMed ID: 4826546
    [No Abstract]   [Full Text] [Related]  

  • 62. [The beneficial effects of immunostimulating and antiviral therapy on ophthalmic zona].
    Topciu V; Chercotă G; Mihăilescu R; Nadolnic A
    Rev Roum Virol; 1993; 44(1-2):91-5. PubMed ID: 8043484
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of aerobic and anaerobic corynebacteria on reaginic antibody response in mice.
    Adachi H; Yabu-Uchi K; Ozawa K; Sindo T; Tadokoro I
    Microbiol Immunol; 1978; 22(1):53-6. PubMed ID: 661628
    [No Abstract]   [Full Text] [Related]  

  • 64. Monocytes and macrophages in malignant melanoma IV. Effects of C. parvum on monocyte function.
    Hedley DW; Nyholm RE; Currie GA
    Br J Cancer; 1979 May; 39(5):558-65. PubMed ID: 486312
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [ISOLATION OF ISOPENTADECANOIC AND ISOHEPTADECANOIC ACIDS FROM THE LIPIDS OF CORYNEBACTERIUM PARVUM].
    ETEMADI AH
    Bull Soc Chim Biol (Paris); 1963; 45():1423-32. PubMed ID: 14104126
    [No Abstract]   [Full Text] [Related]  

  • 66. Chemoattractant properties of Corynebacterium parvum and pyran copolymer for human monocytes and neutrophils.
    Majeski JA; Stinnett JD
    J Natl Cancer Inst; 1977 Mar; 58(3):781-3. PubMed ID: 839571
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A randomized study of adjuvant immunotherapy with levamisole and Corynebacterium parvum in operable non-small cell lung cancer.
    Fox RM; Woods RL; Tattersall MH; Basten A
    Int J Radiat Oncol Biol Phys; 1980 Aug; 6(8):1043-5. PubMed ID: 6998933
    [No Abstract]   [Full Text] [Related]  

  • 68. Clinical immunoadjuvant studies with tilorone, DEAA fluorene (RMI 11,002da), and Corynebacterium parvum and some observations on the role of host resistance and herpes-like lesions in tumor growth.
    Regelson W
    Ann N Y Acad Sci; 1976; 277(00):269-87. PubMed ID: 187101
    [No Abstract]   [Full Text] [Related]  

  • 69. Enhanced resistance of mice to infection with bacteria following pre-treatment with Corynebacterium parvum.
    Adlam C; Broughton ES; Scott MT
    Nat New Biol; 1972 Feb; 235(59):219-20. PubMed ID: 4501536
    [No Abstract]   [Full Text] [Related]  

  • 70. The in vitro killing of syngeneic cells by peritoneal cells from adjuvant-stimulated mice.
    Jones JT; McBride WH; Weir DM
    Cell Immunol; 1975 Aug; 18(2):375-83. PubMed ID: 1139640
    [No Abstract]   [Full Text] [Related]  

  • 71. Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects.
    Purves EC; Snell M; Cope WA; Addison IE; Copland RF; Berenbaum MC
    Br J Urol; 1979 Aug; 51(4):278-82. PubMed ID: 380732
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Glucagon suppressed proliferation rate of mammary aplastic carcinoma in mice.
    Pavelić K; Pavelić J
    Horm Metab Res; 1980; 12(6):243-6. PubMed ID: 7409736
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Some "pharmacologic' data about Corynebacterium parvum.
    Israel L
    Recent Results Cancer Res; 1980; 75():88-91. PubMed ID: 7232843
    [No Abstract]   [Full Text] [Related]  

  • 74. The long-standing history of Corynebacterium parvum, immunity, and viruses.
    Palmieri B; Vadalà M; Roncati L; Garelli A; Scandone F; Bondi M; Cermelli C
    J Med Virol; 2020 Nov; 92(11):2429-2439. PubMed ID: 32472706
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Aspartate-assisted immune stimulation: its importance in antitumor and antiviral protection.
    Chany C; Cerutti I
    Int J Cancer; 1986 Aug; 38(2):259-64. PubMed ID: 2426209
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [The so-called adjuvant Corynebacterium parvum].
    Günther O
    Dtsch Med Wochenschr; 1978 Jan; 103(2):84-5. PubMed ID: 304802
    [No Abstract]   [Full Text] [Related]  

  • 77. Mitogenicity of Corynebacterium parvum for mouse lymphocytes.
    Zola H
    Clin Exp Immunol; 1975 Dec; 22(3):514-21. PubMed ID: 817854
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of Corynebacterium parvum on the class and subclass of antibody produced in the response of different strains of mice to sheep erythrocytes.
    Warr GW; James K
    Immunology; 1975 Mar; 28(3):431-42. PubMed ID: 1092609
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of macrophages in the adjuvant effect on antibody production of Corynebacterium parvum.
    Watson SR; Sljivić VS
    Clin Exp Immunol; 1976 Jan; 23(1):149-53. PubMed ID: 770033
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in normal mice.
    Wolmark N; Levine M; Fisher B
    J Reticuloendothel Soc; 1974 Oct; 16(4):252-7. PubMed ID: 4455907
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.